The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

Q3 2024 Management View CEO Matt Gline highlighted 2025 as a year of major milestones, focusing on validating the anti-FcRn franchise with upcoming MG and CIDP data and a central registrational ...

The FSR Pilot Grant program, initiated in 2018, seeks to fund innovative research in both clinical and basic science settings ...

Dennis’ dad died of a condition called sarcoidosis when he was 39, and Dennis is now 38, which raises some concerns. In the next episode, we learn that Dennis has some symptoms that can indicate ...

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

Efzofitimod, the company's first-in-class biologic immunomodulator, is in clinical development for the treatment of interstitial lung diseases or ILD such as pulmonary sarcoidosis. The posters ...

Considering taking supplements to treat sarcoidosis? Below is a list of common natural remedies used to treat or reduce the symptoms of sarcoidosis. Follow the links to read common uses ...

The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...

It may be that the tattoo ink acts as an immunological trigger to the development of (cutaneous) sarcoidosis. Acknowledgment: We wish to thank the photography department at Hautklinik Uniklinikum ...

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline ...